Marker Therapeutics is dedicated to the development and commercialization of next-generation T cell-based immunotherapies for patients with a wide range of blood cancers and solid tumors. Our team is comprised of talented and passionate professionals with deep expertise in cancer immunotherapy and driven by an urgency to deliver effective treatments to patients who currently have few or no therapeutic options.
Leveraging millions of years of immunologic evolution, our Multi-Antigen Recognizing T cell (MAR-T cell) therapy provides patients with natural T cells capable of recognizing and killing tumor cells effectively. Our MAR-T cell technology was developed at Baylor College of Medicine and uses non-genetically engineered T cells to recognize multiple tumor targets. We believe that MAR-T cells provide a safe, potent, and durable anti-cancer activity. To date, our MAR-T cell technology has been studied in hundreds of patients with various forms of hematological malignancies and solid tumors, demonstrating an excellent safety profile and broad potential for our unique MAR-T cell platform.
